Evidence map›Paper›PMID 30924134›Full record

ArticleBritish journal of haematology2019

Quantitative sensory testing in children with sickle cell disease: additional insights and future possibilities.

Robin E Miller, Dawn S Brown, Scott W Keith, Sarah E Hegarty, Yamaja Setty, Claudia M Campbell, Suzanne M McCahan, Suhita Gayen-Betal, Hal Byck, Marie Stuart

Open access · hybridAbstract read
In one paragraph

Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Robin E MillerNemours Center for Cancer and Blood Disorders, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.ORCID 0000-0001-9530-6181
Dawn S BrownNemours Center for Cancer and Blood Disorders, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Scott W KeithDivision of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Sarah E HegartyDivision of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Yamaja SettyNemours Center for Cancer and Blood Disorders, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Claudia M CampbellDepartment of Psychiatry and Behavioral Health, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Suzanne M McCahanBioinformatics Core Facility, Nemours Biomedical Research, Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Suhita Gayen-BetalNemours Center for Cancer and Blood Disorders, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Hal ByckDepartment of Pediatrics, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Marie StuartNemours Center for Cancer and Blood Disorders, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE, USA.
Alfred I. duPont Hospital for Children · USThomas Jefferson University · USJohns Hopkins University · US

Funding

Subproject Title: Clinical Research Education, Mentoring and Career Development CoreU54GM104941 · NIGMS · UNIVERSITY OF DELAWARE · PI Megan M Wenner · 2013 to 2026
$60.5M
The eye as a window into sickle cell disease morbidityP20GM109021 · NIGMS · NEMOURS CHILDREN'S HOSPITAL, DELAWARE · PI BROUSSEAU, DAVID C · 2014 to 2025
$20.7M
NIGMS NIH HHS P20 GM109021NIGMS NIH HHS U54 GM104941
6 · The paper itself

Abstract

Quantitative sensory testing (QST) is used in a variety of pain disorders to characterize pain and predict prognosis and response to specific therapies. In this study, we aimed to confirm results in the literature documenting altered QST thresholds in sickle cell disease (SCD) and assess the test-retest reliability of results over time. Fifty-seven SCD and 60 control subjects aged 8-20 years underwent heat and cold detection and pain threshold testing using a Medoc TSAII. Participants were tested at baseline and 3 months; SCD subjects were additionally tested at 6 months. An important facet of our study was the development and use of a novel QST modelling approach, allowing us to model all data together across modalities. We have not demonstrated significant differences in thermal thresholds between subjects with SCD and controls. Thermal thresholds were consistent over a 3- to 6-month period. Subjects on whom hydroxycarbamide (HC) was initiated shortly before or after baseline testing (new HC users) exhibited progressive decreases in thermal sensitivity from baseline to 6 months, suggesting that thermal testing may be sensitive to effective therapy to prevent vasoocclusive pain. These findings inform the use of QST as an endpoint in the evaluation of preventative pain therapies.

Indexed as

AdolescentAnemia, Sickle CellCase-Control StudiesChildFemaleHumansMalePainPain ThresholdQuantitative Structure-Activity Relationshippressure pain thresholdquantitative sensory testingsickle cell diseasethermal thresholdsvasoocclusive pain

Identifiers

PMID30924134
PMCPMC6563447
OpenAlexW2934819205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.